Clinical Trials Logo

Enoxaparin clinical trials

View clinical trials related to Enoxaparin.

Filter by:
  • None
  • Page 1

NCT ID: NCT06357403 Recruiting - Pulmonary Embolism Clinical Trials

Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients

AntiXa-ICU
Start date: May 4, 2024
Phase:
Study type: Observational

The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and/or pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are: - What is the association between antiXa and VTE? - What is the association between antiXa and symptomatic, respectively incidental, VTE? - How is pharmacological anticoagulation with enoxaparin related to measured antiXa? - What is the association between antiXa and bleeding complications. - What is the incidence of venous thromboembolism in patients treated at an intensive care unit? - How is the occurence of VTE related to patient-centred outcomes such as mortality, quality of life, length of stay and days outside of the intensive care unit/hospital.

NCT ID: NCT04402762 Completed - Enoxaparin Clinical Trials

Pharmacodynamic Equivalence of Ovine Enoxaparin to Lovenox®

Start date: December 20, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed as a randomized, open-label, 2-way cross-over, single dose study with at least 7 days wash-out period. The objective of this study is to demonstrate the pharmacodynamic / pharmacokinetic equivalence of ovine enoxaparin to the reference product, the originator porcine enoxaparin, Lovenox® from Sanofi, and to assess its safety and tolerability in healthy volunteers.

NCT ID: NCT03528967 Completed - Clinical trials for Placental Insufficiency

Enoxaparin in the Prevention of Placental Insufficiency in Pregnant Women

PRESANCE
Start date: October 23, 2013
Phase: Phase 4
Study type: Interventional

Assessment of the effectiveness of Enoxaparin, at a preventive dose, combined with Aspirin treatment versus Aspirin only treatment in reducing placental insufficiency in pregnant women.